Edarbyclor Side Effects

If you are undergoing high blood pressure treatment with Edarbyclor, contact your healthcare provider right away if you develop fainting, decreased urine production, or other potentially serious problems. In most cases, reactions to this drug tend to be minor and easy to treat. The most commonly reported side effects of Edarbyclor include dizziness and fatigue.

An Introduction to Edarbyclor Side Effects

Just like any medicine, Edarbyclor™ (azilsartan/chlorthalidone) can cause side effects. However, not everyone who takes the drug will have problems. In fact, most women tolerate it quite well. If side effects do occur, in most cases, they are minor and either require no treatment or are treated easily by you or your healthcare provider.
 
(This article covers many, but not all, of the possible side effects with Edarbyclor. Your healthcare provider can discuss a more complete list with you.)
 

Common Side Effects of Edarbyclor

Edarbyclor has been studied extensively in clinical trials. In these studies, one group of people received Edarbyclor (which contains azilsartan and chlorthalidone), while other groups were given just azilsartan or just chlorthalidone. As a result, it was possible to see what side effects occurred, how often they appeared, and how they compared to the other groups.
 
In clinical studies, the most common Edarbyclor side effects included:
 
  • Dizziness -- in up to 8.9 percent of people
  • Fatigue -- up to 2 percent.
 
Both of these reactions were more common with Edarbyclor than with azilsartan or chlorthalidone alone.
 
10 Foods That Lower Cholesterol

Edarbyclor Medication Information

Referring Pages:
Terms of Use
Advertise with Us
Contact Us
About eMedTV
Privacy Policy
Copyright © 2006-2017 Clinaero, Inc.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.